Compare Appian Corp (APPN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Sana Biotechnology Inc — how do they compare? Appian Corp trades at $34.53 (market cap $2.54B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: Appian Corp is far larger — about 2.2× Sana Biotechnology Inc's market cap, and Appian Corp is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| APPN | SANA | |
|---|---|---|
Market Cap | $2.54B | $1.13B |
Sector | Technology | Health |
52-Week High | $45.64 | $5.92 |
52-Week Low | $18.72 | $2.68 |
Enterprise Value | $2.67B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $34.42, down 3.26% on the day, following recent earnings beats but amid broader software stock volatility. The stock shows a bullish technical trend with moving averages supporting upside, though oscillators indicate overbought conditions. Fundamentally, revenue growth remains strong with 2025 revenue at $726.94 million and a return to positive net income of $1.23 million, yet profitability metrics like ROE at -936.62% highlight ongoing challenges. Recent news highlights AI-driven partnerships and enterprise demand as key growth catalysts.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating (63.16% hold) and a $32.50 price target below the current price, signaling limited near-term upside. Risks include high debt levels, negative equity, and competitive pressures in low-code software. Investment appeal hinges on sustained AI adoption and margin improvement, but volatility and weak shareholder equity pose significant risks.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
